CRISPR Therapeutics AG
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Samarth Kulkarni Ph.D.
- Full Time Employees
- 407
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Baarerstrasse 14 Zug Switzerland 6300
- IPO Date
- Oct 19, 2016
- CIK
- 0001674416
- Website
- crisprtx.com
- Similar Companies
- Business
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Company News
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
This Healthcare Growth Stock Could Be a Steal of a Deal Right Now
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
3 Dirt Cheap Stocks to Buy Right Now
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
Crispr Therapeutics: Prepare To Be Bored
1 Biotech Stock Down 62% to Buy and Hold
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
2 Biotech Bets to Buy in September
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
3 Monster Biotech Stocks to Buy Before 2025
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
Crispr's Casgevy Launch: Promising Start, Uncertain Future
3 Gene Editing Stocks with Potential to Transform Medicine